However, the dose-limiting toxicities of the CDK4/6 inhibitors and the inevitable resistance of tumor cells toward them have limited their clinical application, with the exception of ER+ metastatic breast cancer [44, 45]. The gene discussed is CDK4; the disease is neoplasm.